The team members cautioned that this treatment was tested in animal models, but not yet on human cancer patients. Nevertheless, they said the discovery contributes to a promising new focus for cancer research: disrupting the biochemical activity that ...
Celyad SA (CYAD) Receives Additional US Patent for Cancer Treatment based on TCR-deficient CAR-T Cells
Celyad (NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, today announced the issuance of United States Patent No.
No comments:
Post a Comment